These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36659846)

  • 1. [Rheumatoid Arthritis].
    Lehmann J; Kyburz D
    Ther Umsch; 2023 Feb; 80(1):27-33. PubMed ID: 36659846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
    Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
    Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
    Burgers LE; Boeters DM; Reijnierse M; van der Helm-van Mil AHM
    Arthritis Res Ther; 2018 Apr; 20(1):68. PubMed ID: 29636084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early arthritis: action desired - treatment required].
    Köller M; Nöbauer-Huhmann I
    Wien Med Wochenschr; 2009; 159(3-4):66-9. PubMed ID: 19247592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core management principles in rheumatoid arthritis to help guide managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S03-8. PubMed ID: 22073933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of early treatment for the prognosis of rheumatoid arthritis.
    Kyburz D; Finckh A
    Swiss Med Wkly; 2013; 143():w13865. PubMed ID: 24089023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of disease activity and treatment outcomes in rheumatoid arthritis.
    Farheen K; Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S09-13. PubMed ID: 22073934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
    Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
    Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Characteristics and Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-year Followup Study.
    Brinkmann GH; Norli ES; Kvien TK; Haugen AJ; Grøvle L; Nygaard H; Bjørneboe O; Thunem C; Mjaavatten MD; Lie E
    J Rheumatol; 2017 Feb; 44(2):154-161. PubMed ID: 28089976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
    J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
    Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
    J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.